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Background: Indacaterol is an inhaled, once-daily, ultra-long-acting b2-agonist for the treatment of
chronic obstructive pulmonary disease (COPD). We report on the effectiveness of indacaterol and other
bronchodilators compared with placebo in patients across the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) 2011 categories A to D.
Methods: A post-hoc, subgroup pooled analysis of 6-month efﬁcacy data from three randomized,
placebo-controlled, parallel-group studies involving 3862 patients was performed across GOLD 2011
categories A to D, according to baseline forced expiratory volume in 1 s (FEV1) % predicted, modiﬁed
Medical Research Council (mMRC) dyspnea scale, and exacerbation history in the 12 months prior to
entry. Efﬁcacy of once-daily indacaterol 150 and 300 mg, open-label tiotropium 18 mg, twice-daily sal-
meterol 50 mg, and formoterol 12 mg was compared with placebo. End points analysed were trough FEV1,
transition dyspnea index (TDI), and St George's Respiratory Questionnaire (SGRQ) total score, all at Week
26, and mean rescue medication use over 26 weeks.
Results: Indacaterol 150 and 300 mg signiﬁcantly improved FEV1, compared with placebo across all GOLD
groups. Indacaterol 150 and 300 mg also signiﬁcantly improved TDI, SGRQ total score, and mean rescue
medication use compared with placebo across most GOLD subgroups.
Conclusions: Treatment selection according to patient's symptoms as well as lung function is an
important consideration in maintenance treatment of COPD. Indacaterol 150 and 300 mg effectively
improved lung function and symptoms in patients across all GOLD 2011 categories.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
A major revision to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) strategy document was published in 2011, inMedicine and Tuberculosis,
ddress AA11, Postbox 30.001,
0280; fax: þ31 50 36 19320.
M. Kerstjens), gdeslee@chu-
), james_donohue@med.unc.
ions.com (D. Young), david-1.
rnmann@ikf-pneumologie.de
r Ltd. This is an open access articlewhich patients with chronic obstructive pulmonary disease (COPD)
were classiﬁed according to symptoms and exacerbation risk,
rather than lung function alone [1]. This document included sug-
gestions for treatment choices, however, these recommendations
were based on studies with populations selected with previous
GOLD classiﬁcations, according to FEV1 % predicted alone, and had
no direct backing with data [2e4]. The authors of the GOLD strategy
document anticipated that the new classiﬁcation scheme would
encourage new studies to generate more supporting evidence. Ul-
timately, these should be prospective randomized controlled trials
selecting patients based on the new classiﬁcation; however, there
will be a long lead time before publication of data from such
studies. In the meantime, existing data sets can be re-analyzedunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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categorizing patient groups with different impact of COPD and in
guiding therapeutic choices. Assessing the effects of treatments per
category A to D should help in building the evidence base under the
choices made in the GOLD document.
Therefore, the purpose of this post-hoc analysis was to assess
the efﬁcacy of the once-daily long-acting b2-agonist (LABA) inda-
caterol versus placebo across different patient categories as closely
aligned to GOLD 2011 as the data allowed. The magnitude of effect
was also compared with the currently available bronchodilators,
twice-daily LABAs formoterol and salmeterol, and the once-daily
long-acting muscarinic antagonist (LAMA) tiotropium.
Data from three clinical studies [5e7] were pooled for this post-
hoc analysis. Endpoints includedmeasurement of airﬂow limitation
using trough FEV1 (mean of 23 h 10 min and 23 h 45 min post-dose
readings), breathlessness symptoms using the transition dyspnea
index (TDI), and health status using St Georges Respiratory Ques-
tionnaire (SGRQ) total score, all at week 26, and the mean rescue
medication use (salbutamol/albuterol) over 26 weeks.
2. Methods
2.1. Study design
We conducted a pooled analysis of 6-month patient-level efﬁ-
cacy data from three Phase III, randomized studies, for which pri-
mary outcomes have been previously published. The studies
selected had similar inclusion and exclusion criteria, similar end-
points, and included the main bronchodilators used in the treat-
ment of COPD. These studies were: INdacaterol: Value in COPD:
Longer term Validation of Efﬁcacy and safety (INVOLVE,
Clinicaltrials.gov registration number NCT00393458), a double-
blind comparison of indacaterol 300 mg or 600 mg once daily with
placebo and formoterol 12 mg twice daily for 52 weeks (data from
the indacaterol 600 mg treatment group are excluded from this
pooled analysis as this dose is not approved in any country) [5];
INdacaterol versus tiotropium to Help Achieve New COPD treat-
ment Excellence (INHANCE, NCT00463567), which compared
double-blind indacaterol 150 mg or 300 mg once daily with placebo
and open-label tiotropium 18 mg once daily for 26 weeks [6]; and
INdacaterol: efﬁcacy evaLuation usInG 150 mg doses witH COPD
PatienTs (INLIGHT 2, NCT00567996), a 26-week study comparing
double-blind indacaterol 150 mg once daily with placebo and sal-
meterol 50 mg twice daily [7].
2.2. Patients
All three studies sought to enroll patients with a clinical diag-
nosis of moderate-to-severe COPD [using the GOLD 2005 criteria,
i.e., post-bronchodilator FEV1 <80% and 30% of the predicted
normal value, post-bronchodilator FEV1/forced vital capacity
(FVC) < 70%]. Other inclusion criteria were: males and females aged
40 years with a smoking history of at least 20 pack-years. All had
trough FEV1 as primary end-point. Study designs and detailed in-
clusion and exclusion criteria of the individual studies have been
published previously [5e7].
For the purposes of this analysis, patients were classiﬁed as A, B,
C, or D using GOLD 1e4 classiﬁcation of airﬂow limitation, history
of exacerbations, and patient reported symptoms, according to the
following criteria: category A: mMRC < 2, and GOLD 1 or 2
(FEV1  50% predicted), and no history of exacerbations in the
previous year; category B: mMRC  2, and GOLD 1 or 2, and no
history of exacerbations in the previous year; category C:
mMRC < 2, and GOLD 3 or 4 (FEV1 < 50% predicted) and/or one or
more exacerbations in the previous year; and category D:mMRC  2, and GOLD 3 or 4 and/or one or more exacerbations in
the previous year. The assessment pointing to the highest risk was
used, thus matching the GOLD recommendations.
An adjustment had to bemade as exacerbation history (in the 12
months before recruitment) was only available as “Yes” or “No” in
the study database, whereas the GOLD strategy document classiﬁes
patients according to the number of exacerbations (0e1 or 2þ).
Inhaler technique in all three studies was assessed by in-
vestigators/staff at the screening and randomization visits. Study
drug compliance was assessed by the investigator and/or center
personnel at designated visits by recording capsule counts/dose
counter readings, as well as information provided by the patient/
caregiver.
All participants in the three studies provided written informed
consent, and all study protocols were approved by the independent
ethics committee/institutional review board at each study site in
the respective participating country. All three studies were con-
ducted in compliance with good clinical practice and in accordance
with the Declaration of Helsinki.
2.3. End points
2.3.1. Lung function
The primary end point analysed was trough FEV1 at Week 26
measured using standard spirometry according to ATS/ERS guide-
lines (mean of 23 h 10 min and 23 h 45 min post-dose readings,
based on the time of the previous morning dose. This time point
was 12 h after the second dosing for the twice daily bronchodilators
formoterol and salmeterol). A difference versus placebo in trough
FEV1 of 120 mL was considered as the minimum clinically impor-
tant difference (MCID). This is the mid-point of the 100e140 mL
range reported as the MCID by the American Thoracic Society/Eu-
ropean Respiratory Society [8].
2.3.2. Health status and dyspnea
Health status was assessed using the SGRQ questionnaire and
dyspneawas assessed using the TDI questionnaire. SGRQ total score
and the odds ratio (OR) for the percentage of patients achieving 4
unit improvement from baseline (the MCID for SGRQ [9]) and TDI
total score and OR for the percentage of patients achieving the
MCID of 1 unit improvement from the Baseline Dyspnea Index
(BDI) score [10] were assessed at Week 26.
2.3.3. Rescue medication
Patients recorded their use of rescue medication (number of
puffs) twice daily in patient diaries. Rescue medication (salbuta-
mol/albuterol MDI) use in terms of change from baseline in number
of puffs/day and % days with no rescue medication use was
measured over 26 weeks.
2.3.4. Statistical analysis
Trough FEV1 after 26 weeks of treatment was analyzed using a
mixed-model analysis of covariance (ANCOVA), with treatment,
baseline ICS use, smoking status, and study as ﬁxed effects and
baseline FEV1 and FEV1 reversibility as covariates. Center nested
within country was included as a random effect. To assess the
treatment effect across the GOLD risk categories, a ﬁxed effect for
risk group and a treatment by risk group interaction were included
in themodel. The samemodel (with appropriate baseline) was used
to analyze SGRQ and TDI total scores as well as change from
baseline in puffs of rescue medication per day and percentage of
days with no rescue use. Data are presented as least squares means
with standard errors (SE) or associated 95% conﬁdence intervals
(CI) for differences between treatments. The proportion of patients
achieving MCID in FEV1, TDI, and SGRQ was analyzed using a
Table 1
Patient characteristics at baseline by GOLD 2011 category in the pooled analysis data set.
GOLD 2011 category A B C D
N 1134 1008 622 1078
Age, mean (SD) years 63 (8.9) 64 (9.2) 62 (8.4) 64 (8.3)
65, % 46.5 51.9 42.9 47.2
Sex, % male 70.2 63.5 78.0 75.1
Current smoker, % 44.7 42.3 44.7 43.8
Mean (SD) pack years 46 (28.0) 46 (23.7) 44 (21.8) 46 (21.8)
Inhaled corticosteroid use, yes (%) 39.4 39.3 52.3 50.1
Spiromety e post salbutamol administration
FEV1  50% predicted, % 100.0 100.0 6.3 5.6
FEV1 <50% predicted, % 0.0 0.0 93.7 94.4
mMRC score
<2 1134 0 622 0
2 0 1008 0 1078
Patients with exacerbation in past year, n (%) 0 0 72 (11.6) 149 (13.8)
Mean (SD) duration of COPD, years 6.0 (6.07) 6.8 (6.45) 7.0 (6.98) 7.4 (6.20)
Mean (SD) FEV1 predicted, % 65.2 (9.57) 63.2 (9.71) 43.2 (8.15) 41.2 (7.92)
Mean (SD) FEV1/FVC ratio, % 57.3 (8.39) 56.8 (8.78) 47.5 (8.84) 46.1 (9.63)
Baseline rescue use, mean puffs/day 2.2 (2.67) 3.3 (3.42) 3.1 (3.27) 4.6 (4.08)
Mean (SD) baseline SGRQ total score 34.3 (15.68) 48.7 (16.80) 38.8 (15.49) 54.0 (16.31)
Mean (SD) BDI total score 8.0 (1.92) 5.9 (1.88) 7.2 (1.90) 5.3 (1.88)
BDI, baseline dyspnea index; FEV1, forced expiratory volume in 1 s; SD, standard deviation; SGRQ, St George's Respiratory Questionnaire.
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associated 95% CI for the analysis of percentages of patients. All
covariates were the same as the ANCOVAmodel with the exception
of country which, due to convergence issues, was replaced by re-
gion (North America, South America, Europe, other).
All analyses were performed using SAS version 9.3. No powering
or sample size calculations were performed for these post-hoc
analyses, and no adjustment was made for multiplicity.
3. Results
3.1. Patients
Patient distribution across the four GOLD 2011 categories is
shown in Table 1. Mean age and current smoking status were
similar across the categories. Patient numbers by treatment used in
the analysis are shown in Table 2. Inhaler technique in all patients
was regarded as acceptable according to recommended use.
Compliance to treatment was high across all three studies, over 96%
for all treatment groups.
3.2. Trough FEV1
The highest overall improvement in trough FEV1 versus placebo
at Week 26 for all bronchodilators except formoterol was seen in
Group A (Fig. 1). In all categories, indacaterol 150 mg improved
trough FEV1 versus placebo by a statistically signiﬁcant (p < 0.0001)
and clinically relevant (>120 mL) amount. Improvements with
other treatments were not as consistent across categories; notTable 2
Patient numbers by treatment in GOLD 2011 category.
Treatment A B
n (% of treatment group)
N ¼ 1134
n (% of treatment group)
N ¼ 1008
Indacaterol 150 mg 223 (29.9) 203 (27.2)
Indacaterol 300 mg 234 (28.6) 232 (28.3)
Formoterol 12 mg 106 (26.6) 115 (28.9)
Salmeterol 50 mg 110 (33.1) 65 (19.6)
Tiotropium 18 mg 111 (27.0) 121 (29.4)
Placebo 350 (30.7) 272 (23.9)achieving clinical signiﬁcance in all categories or signiﬁcance
against placebo. The ORs for achieving MCID versus placebo were
similar with indacaterol 150 mg, 300 mg, and tiotropium (Fig. 2).
3.3. SGRQ
Indacaterol 150 mg was the only bronchodilator to exhibit a
signiﬁcant improvement in SGRQ versus placebo in all four GOLD
categories. All active treatments gave statistically signiﬁcant im-
provements versus placebo in categories B and C (Fig. 3). The ORs
for percentage of patients achieving the MCID are presented in
Fig. 4.
3.4. TDI
Indacaterol 300 mg achieved a signiﬁcant mean treatment effect
versus placebo in excess of the MCID consistently across all cate-
gories (Fig. 5). Indacaterol 150 mg achieved a signiﬁcant mean
treatment effect versus placebo in excess of the MCID in categories
A, B, and C. Patients receiving indacaterol 150 and 300 mg were
signiﬁcantly more likely to experience a clinically relevant
improvement in TDI than those receiving placebo is all GOLD cat-
egories (Fig. 6).
3.5. Rescue salbutamol use
In all GOLD categories, the mean rescue medication use was
statistically signiﬁcantly reduced with indacaterol 150 and 300 mg,
formoterol, and salmeterol versus placebo (p < 0.0001, Fig. 7). The %C D Total sample
n (% of treatment group)
N ¼ 622
n (% of treatment group)
N ¼ 1078
n (% of total)
N ¼ 3862
118 (15.8) 201 (26.9) 746 (19.3)
133 (16.2) 217 (26.5) 819 (21.2)
63 (15.8) 114 (28.6) 398 (10.3)
61 (18.4) 96 (28.9) 333 (8.6)
62 (15.1) 117 (28.5) 415 (10.8)
185 (16.2) 333 (29.2) 1151 (29.8)
Fig. 1. Effect of treatments (activeeplacebo difference) on trough FEV1 at Week 26 by GOLD 2011 category. Data are least squares means ± 95% conﬁdence interval. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 versus placebo; yp < 0.05, yyp < 0.01, yyyyp < 0.0001 for difference versus formoterol; zp < 0.05 for difference versus tiotropium; xp < 0.05,
xxp < 0.01 for difference versus salmeterol. Dashed line represents the minimum clinically important difference (MCID) between active and placebo treatments. FEV1, forced
expiratory volume in 1 s; FOR, formoterol 12 mg; IND 150, indacaterol 150 mg; IND 300, indacaterol 300 mg; SAL, salmeterol 50 mg; TIO, tiotropium 18 mg.
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placebo for both indacaterol doses and for formoterol, but not
consistently so for salmeterol and tiotropium (Supplementary
Fig. 1).
4. Discussion
This post-hoc analysis of three pooled clinical studies aimed to
compare the LABAs indacaterol, LABAs salmeterol and formoterol,
and LAMA tiotropium against placebo in terms of lung function,
symptom scores, health-related quality of life, and rescue medica-
tion use. All of these measures are important goals in the man-
agement of COPD. The current GOLD strategy for COPD treatment
emphasizes the need to assess the impact of the disease by patient-
reported symptoms through mMRC, CAT or CCQ questionnaires,
and the risk of exacerbations in terms of exacerbation history or
lung function. These assessments group patients into four cate-
gories of COPD severity (A, B, C, and D). On the basis of this cate-
gorization, the pooled analysis here allows for the assessment of
the effectiveness of indacaterol and other bronchodilators in pa-
tients with differing severities of COPD.
Patient distribution in this pooled analysis of three studies il-
lustrates the characteristics of patients with COPD recruited into
clinical trials (Table 1). The order of mMRC score fromworst to best
was D-B-C-A. A similar order was observed for SGRQ and BDI score,
partially validating the chosen categorization on the symptom
score axis. Mean duration of COPD increased linearly from category
A to D, however, there was no large difference between categories.
This is consistent with the results from other analyses, suggesting
that disease progression is dependent on many factors that are
patient speciﬁc [11e13]. There was also no clear pattern between
the GOLD groups in our analysis in terms of age or smoking status.ICS use was greater in categories C and D, in line with GOLD rec-
ommendations in patients with frequent exacerbation history [1],
although a signiﬁcant percentage of patients were on ICS in cate-
gories A and B.
Indacaterol 150 mg performed well across all categories and
consistently achieved improvements in more end points than for-
moterol, salmeterol, and tiotropium. Overall, in category B (for
which a LABA is one of the recommended ﬁrst choices) indacaterol
150 and 300 mg consistently gave the greatest improvements
compared with placebo in FEV1, TDI, and rescue medication use.
Supporting these data, a network meta-analysis of several trials
[14] concluded that indacaterol 150 and 300 mg were associated
with greater improvements in FEV1 and SGRQ compared with
glycopyrronium, tiotropium, salmeterol, and formoterol in patients
with moderate-to-severe COPD. The results of the current pooled
analysis provide further evidence for the effectiveness of treatment
with indacaterol 150 and 300 mg, in terms of both lung function and
symptom scores, across all GOLD subcategories.
Patients in category A, for whom SABA or SAMA is the recom-
mended ﬁrst choice according to the GOLD strategy, responded
remarkably well to all of the active treatments, with signiﬁcant
improvements in lung function, symptoms, and rescue medication
use, suggesting a beneﬁt in providing long-acting bronchodilators
to these patients. This provides additional support for the state-
ment in the GOLD strategy document that long-acting bronchodi-
lators are more effective than short-acting formulations at
producing maintained symptom relief [1]. Patients in categories C
and D, for whom the GOLD strategy lists mono-LAMA as one of the
treatment options, were also able to gain substantial beneﬁt from
LABA monotherapy, although the SGRQ and TDI total scores in
category D suggest that intensiﬁcation of therapy (e.g., LABA and
LAMA combination) may be needed.
Fig. 2. Odds ratios (active vs placebo) and associated 95% CI for achieving MCID in trough FEV1 at Week 26 by GOLD 2011 category. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
versus placebo; FEV1, forced expiratory volume in 1 s; MCID, minimum clinically important difference.
Fig. 3. Effect of treatments (activeeplacebo differences) on SGRQ total score at 26 weeks by GOLD 2011 category. Data are least squares means ± 95% conﬁdence interval. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 versus placebo. Dashed line represents the MCID between active and placebo treatments. FOR, formoterol 12 mg; IND 150, indacaterol 150 mg;
IND 300, indacaterol 300 mg; MCID, minimum clinically important difference; SAL, salmeterol 50 mg; SGRQ, St George's Respiratory Questionnaire; TIO, tiotropium 18 mg.
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Fig. 4. Odds ratios (active vs placebo) and associated 95% CI for achieving MCID in SGRQ total score (4 points) at Week 26 by GOLD 2011 category. *p < 0.05, **p < 0.01,
****p < 0.0001 versus placebo; MCID, minimal clinically important difference; SGRQ, St George's Respiratory Questionnaire.
Fig. 5. Effect of treatments (activeeplacebo differences) on TDI total score at Week 26 by GOLD 2011 category. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus placebo;
zp < 0.05 for difference versus tiotropium; ¶p < 0.05 versus indacaterol 150 mg. Dashed line represents the MCID between active and placebo treatments. FOR, formoterol 12 mg; IND
150, indacaterol 150 mg; IND 300, indacaterol 300 mg; MCID, minimal clinically important difference; SAL, salmeterol 50 mg; TDI, transition dyspnea index; TIO, tiotropium 18 mg.
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Fig. 6. Odds ratios (active vs placebo) and associated 95% CI for achieving MCID in TDI total score (1 point) at Week 26 by GOLD 2011 category. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 versus placebo. MCID, minimum clinically important difference; TDI, transition dyspnea index.
Fig. 7. Mean change from baseline in rescue use (activeeplacebo differences) by GOLD 2011 category. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus placebo; yp < 0.05 for
difference versus formoterol; zp < 0.05; zzp < 0.01 for difference versus tiotropium; xxp < 0.01 for difference versus salmeterol; ¶¶p < 0.01 versus indacaterol 150 mg. FOR, formoterol
12 mg; IND 150, indacaterol 150 mg; IND 300, indacaterol 300 mg; SAL, salmeterol 50 mg; TIO, tiotropium 18 mg.
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including lung function, patient symptoms, and future risk of ex-
acerbations. For this reason, treatments should be selected ac-
cording to individual patient requirements in order to provide the
greatest beneﬁt. Given the lack of data from clinical trials specif-
ically designed around the current GOLD classiﬁcation, the current
analysis provides perhaps the best available category of data to
support the choice of therapies.
There are some limitations of the present study including that it
was a post-hoc analysis. Administration of tiotropium as open-label
may have an effect on patient-reported outcomes such as dyspnea
and health status, although a 12-week study using blinded tio-
tropium conﬁrmed a statistically signiﬁcant improvement of inda-
caterol on TDI and SGRQ comparedwith tiotropium [15]. Analysis of
indacaterol trial data has also shown that in subjective measures,
such as SGRQ and TDI, only minimal bias is introduced by the use of
open label tiotropium [16]. Further, the GOLD categories could not
be exactly modeled according to the GOLD 2011 strategy, as the
original studies did not capture the number of exacerbations in the
previous year, only whether there were exacerbations or not. In
terms of exacerbations, GOLD 2011 deﬁned “high risk” as 2 exac-
erbations in the previous year. Of note, according to the updated
(2014) document, a patient who experienced a single exacerbation
resulting in hospitalization would be considered at high risk of
future exacerbations. Finally, the incidence of adverse events was
not analyzed in this post-hoc analysis, however in the original
studies the incidence of adverse events was shown to be compa-
rable across the treatment groups and similar to placebo [5e7].
5. Conclusions
In conclusion, pooling data from several studies and grouping
patients by GOLD category allows comparison of the effectiveness
of long-acting bronchodilators across a spectrum of COPD disease
severity. In this pooled analysis, indacaterol, a once-daily LABA, was
effective in improving lung function, dyspnea, and rescue medica-
tion use across all four recently deﬁned GOLD categories.
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